Hambleton Julie — SEC Form 4 filings
SEC reporting owner CIK 1578771. 11 Form 4 filings on record with FilingPulse; latest filed 2026-06-29.
Transaction summary — filings shown
Covers all 11 filings on record, filed 2024-03-14 to 2026-06-29. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 3 filings — 33,554 shares, $1,128,103 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 13,774 shares @ $53.01 ($730,207) in SpringWorks Therapeutics, Inc., filed 2025-02-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| SpringWorks Therapeutics, Inc. (SWTX) | Director | 5 | — | 5 legs · 18,422 sh · $916,255 | 9 |
| IGM Biosciences, Inc. (IGMS) | Director | 3 | — | 1 leg · 15,132 sh · $211,848 | 4 |
| Erasca, Inc. (ERAS) | Director | 3 | — | — | 3 |
Form 4 filings — Hambleton Julie
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-29 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 29,888 (derivative) @ $0 | EDGAR |
| 2025-08-14 | 4 | IGM Biosciences, Inc. (IGMS) | Disposition to issuer (D): 2,000 | EDGAR |
| 2025-07-02 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Disposition to issuer (D): 14,155 · Disposition to issuer (D): 14,668 (derivative) · Disposition to issuer (D): 15,318 (derivative) · Disposition to issuer (D): 12,216 (derivative) | EDGAR |
| 2025-06-26 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 120,000 (derivative) @ $0 | EDGAR |
| 2025-05-15 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/award (A): 10,060 @ $0 | EDGAR |
| 2025-02-12 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Option exercise (M): 13,774 @ $32.27 · Sale (S): 13,774 @ $53.01 · Option exercise (M): 13,774 (derivative) @ $0 | EDGAR |
| 2024-07-29 | 4 | IGM Biosciences, Inc. (IGMS) | Option exercise (M): 15,132 @ $1.39 · Sale (S): 15,132 @ $14 · Option exercise (M): 15,132 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Erasca, Inc. (ERAS) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-06-05 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Sale (S): 2,946 @ $39.41 · Sale (S): 751 @ $40.57 · Sale (S): 931 @ $41.49 · Sale (S): 20 @ $42.09 | EDGAR |
| 2024-05-17 | 4 | SpringWorks Therapeutics, Inc. (SWTX) | Grant/award (A): 4,095 @ $0 · Grant/award (A): 12,216 (derivative) @ $0 | EDGAR |
| 2024-03-14 | 4 | IGM Biosciences, Inc. (IGMS) | Grant/award (A): 29,400 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1578771 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →